2021
Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies
Palanca-Ballester C, Rodriguez-Casanova A, Torres S, Calabuig-Fariñas S, Exposito F, Serrano D, Redin E, Valencia K, Jantus-Lewintre E, Diaz-Lagares A, Montuenga L, Sandoval J, Calvo A. Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers 2021, 13: 3016. PMID: 34208598, PMCID: PMC8233712, DOI: 10.3390/cancers13123016.Peer-Reviewed Original ResearchLiquid biopsyEpigenetic biomarkersSpecific epigenetic alterationsDNA methylation changesTumor microenvironmentDNA promoter methylationCommon clinical practiceHigh-incidence malignancyActionable genetic alterationsCancer drug responseSingle geneEpigenetic eventsDNA methylationGene setsMethylation changesTypes of cancerEpigenetic alterationsPrimary tumorClinical trialsClinical valueCerebrospinal fluidHigh incidenceTissue biopsiesClinical practiceEarly alterations
2016
Development of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic protein.
Villalba M, Lopez L, Redrado M, Ruiz T, de Aberasturi AL, de la Roja N, Garcia D, Exposito F, de Andrea C, Alvarez-Fernandez E, Montuenga L, Rueda P, Rodriguez MJ, Calvo A. Development of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic protein. Histology And Histopathology 2016, 32: 929-940. PMID: 27995596, DOI: 10.14670/hh-11-857.Peer-Reviewed Original ResearchConceptsTissue microarrayTMPRSS4 protein expressionProtein expressionLarge cell carcinomaNovel tumor typesCancer tissue microarraySquamous carcinomaPoor prognosisCell carcinomaAggressive tumorsCancer deathLung cancerMetastatic spreadDifferent tissue microarraysClinical valueTherapeutic targetTumor typesClinical settingRabbit polyclonal antiserumCancer typesType II serine proteaseHigh expressionTMPRSS4CarcinomaCancer